Jaguar Health Secures $42M in Highly Dilutive Equity Line and Preferred Stock Financing

summarizeSummary

Jaguar Health secured up to $42 million in new financing through an equity line and preferred stock, providing capital but at terms that are highly dilutive to common shareholders.

check_boxKey Events

• New Equity Line of Credit (ELOC)

  The company entered into an ELOC agreement to sell up to $40 million of common stock to an institutional investor. The ELOC has a floor price of $1.10 per share, and the investor will receive $800,000 worth of common stock as commitment shares.

• Series P Preferred Stock Financing

  Jaguar Health closed a private placement of 240 shares of Series P Non-Convertible Preferred Stock for an aggregate purchase price of $2 million. Investors also received pre-funded warrants for $72,000 worth of common stock.

• Highly Dilutive Terms

  The ELOC's floor price of $1.10 and the preferred stock's common stock conversion floor price of $0.546 are significantly below the current stock price of $2.69, indicating substantial potential dilution for existing common shareholders.

• Shareholder Approval Obtained

  Shareholder approval for both the ELOC and the Preferred Stock Financing was obtained on June 8, 2026, allowing the company to proceed with these capital raises.

auto_awesomeAnalysis

Jaguar Health has secured significant capital through a new Equity Line of Credit (ELOC) for up to $40 million and a $2 million private placement of Series P Non-Convertible Preferred Stock. While these financings provide a critical capital runway for the company, especially given its history of financial distress and recent Nasdaq delisting threats, the terms are highly dilutive for existing common shareholders. The ELOC allows the company to sell common stock at prices as low as $1.10 per share, significantly below the current market price of $2.69. The Series P Preferred Stock, which closed on June 9, 2026, carries an 8% annual dividend payable in common stock or cash, with a common stock conversion floor price of $0.546. Both financings include pre-funded warrants and various triggering events that could force redemption into common stock, further increasing dilution. The total potential capital of $42 million is many multiples of the company's current market capitalization, indicating a substantial dilution of existing shareholder value to ensure the company's continued operations.